Identifying Persons with Axial Spondyloarthritis At Risk of Poor Work Outcome: Results from the British Society for Rheumatology Biologics Register

REFERENCES

1. 1.↵
   1. Martindale J,
   2. Shukla R,
   3. Goodacre J

   . The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity. Best Pract Res Clin Rheumatol 2015;29:512–23.

   OpenUrl
2. 2.↵
   1. Espahbodi S,
   2. Bassett P,
   3. Cavill C,
   4. Freeth M,
   5. Hole J,
   6. Sengupta R

   . Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clin Exp Rheumatol 2017;35:571–8.

   OpenUrl
3. 3.↵
   1. van Lunteren M,
   2. Ez-Zaitouni Z,
   3. Fongen C,
   4. Landewé R,
   5. Ramonda R,
   6. van der Heijde D,
   7. et al.

   Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort). Rheumatology 2017;56:2222–8.

   OpenUrl
4. 4.↵
   1. Brown J,
   2. Isaacs D

   . The world cafe: shaping our futures through conversations that matter. San Francisco: Bennett-Koehler Publishers Inc.; 2005.
5. 5.↵
   1. Bevan S,
   2. Brinkley I,
   3. Cooper C,
   4. Bajorek Z

   . 21st century workforces and workplaces. The challenges and opportunities for future work practices and labour markets. London: Bloomsbury Business; 2018.
6. 6.↵
   1. Rudwaleit M,
   2. van der Heijde D,
   3. Landewé R,
   4. Listing J,
   5. Akkoc N,
   6. Brandt J,
   7. et al.

   The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Macfarlane GJ,
   2. Barnish MS,
   3. Jones EA,
   4. Kay L,
   5. Keat A,
   6. Meldrum KT,
   7. et al.

   The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskelet Disord 2015;16:347.

   OpenUrl
8. 8.↵
   1. Reilly MC,
   2. Zbrozek AS,
   3. Dukes EM

   . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353–65.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Reilly MC,
   2. Gooch KL,
   3. Wong RL,
   4. Kupper H,
   5. van der Heijde D

   . Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology 2010;49:812–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Jenkinson TR,
    2. Mallorie PA,
    3. Whitelock HC,
    4. Kennedy LG,
    5. Garrett SL,
    6. Calin A

    . Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.

    OpenUrlPubMed
11. 11.↵
    1. Garrett S,
    2. Jenkinson T,
    3. Kennedy LG,
    4. Whitelock H,
    5. Gaisford P,
    6. Calin A

    . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.

    OpenUrlPubMed
12. 12.↵
    1. Calin A,
    2. Garrett S,
    3. Whitelock H,
    4. Kennedy LG,
    5. O’Hea J,
    6. Mallorie P,
    7. et al.

    A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.

    OpenUrlPubMed
13. 13.↵
    1. Jones SD,
    2. Steiner A,
    3. Garrett SL,
    4. Calin A

    . The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996;35:66–71.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Doward LC,
    2. Spoorenberg A,
    3. Cook SA,
    4. Whalley D,
    5. Helliwell PS,
    6. Kay LJ,
    7. et al.

    Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20–6.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. EuroQoL Group

    . EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Zigmond AS,
    2. Snaith RP

    . The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Chalder T,
    2. Berelowitz G,
    3. Pawlikowska T,
    4. Watts L,
    5. Wessely S,
    6. Wright D,
    7. et al.

    Development of a fatigue scale. J Psychosom Res 1993;37:147–53.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Jenkins CD,
    2. Stanton BA,
    3. Niemcryk SJ,
    4. Rose RM

    . A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988;41:313–21.

    OpenUrlCrossRefPubMed
19. 19.↵
    Ministry of Housing, Communities & Local Government. Index of Multiple Deprivation Score, 2010. [Internet. Accessed September 26, 2018.] Available from: opendatacommunities.org/data/societal-wellbeing/deprivation/imd-score-2010
20. 20.↵
    1. Scottish Executive

    . Scottish Index of Multiple Deprivation 2004: Summary Technical Report. Edinburgh: Scottish Executive; 2004. [Internet. Accessed September 26, 2018.] Available from: www.gov.scot/Publications/2004/06/19429/38161
21. 21.↵
    1. Liang KY,
    2. Zeger SL

    . Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13–22.

    OpenUrlCrossRef
22. 22.↵
    1. Huber PJ

    . The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the fifth Berkeley symposium on mathematical statistics and probability, volume 1: statistics. Berkeley: University of California Press; 1967;1:221–33.

    OpenUrl
23. 23.↵
    1. Jones GT,
    2. Keat A,
    3. Pathan E,
    4. Macfarlane GJ

    . Real-world effectiveness of TNF inhibition in spondyloarthritis. Data from a large nationwide prospective cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis [abstract]. Arthritis Rheumatol 2017;69 Suppl 10:1543.

    OpenUrl
24. 24.↵
    1. Molto A,
    2. Tezenas du Montcel S,
    3. Wendling D,
    4. Dougados M,
    5. Vanier A,
    6. Gossec L

    . Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort. Ann Rheum Dis 2017;76:1036–41.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Ramiro S,
    2. Landewé R,
    3. van Tubergen A,
    4. Boonen A,
    5. Stolwijk C,
    6. Dougados M,
    7. et al.

    Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open 2015;1:e000153.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Villaverde-García V,
    2. Cobo-Ibáñez T,
    3. Candelas-Rodríguez G,
    4. Seoane-Mato D,
    5. Campo-Fontecha PDD,
    6. Guerra M,
    7. et al.

    The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: a systematic literature review. Semin Arthritis Rheum 2017;46:569–83.

    OpenUrl
27. 27.↵
    1. Boonen A,
    2. Brinkhuizen T,
    3. Landewé R,
    4. van der Heijde D,
    5. Severens JL

    . Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 2010;69:1123–8.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. de Hooge M,
    2. Ramonda R,
    3. Lorenzin M,
    4. Frallonardo P,
    5. Punzi L,
    6. Ortolan A,
    7. et al.

    Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Res Ther 2016;18:265.

    OpenUrl
29. 29.↵
    1. Bakland G,
    2. Gran JT,
    3. Becker-Merok A,
    4. Nordvåg BY,
    5. Nossent JC

    . Work disability in patients with ankylosing spondylitis in Norway. J Rheumatol 2011;38:479–84.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Grønning K,
    2. Rødevand E,
    3. Steinsbekk A

    . Paid work is associated with improved health-related quality of life in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:1317–22.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Haglund E,
    2. Petersson IF,
    3. Bremander A,
    4. Bergman S

    . Predictors of presenteeism and activity impairment outside work in patients with spondyloarthritis. J Occup Rehabil 2015;25:288–95.

    OpenUrl
32. 32.↵
    1. Macfarlane GJ,
    2. Jones GT,
    3. Shim J

    . Are work outcomes improved in axial spondyloarthritis (axSpA) patients with biologic therapy? Results from the British Society for Rheumatology Register [abstract]. Arthritis Rheumatol 2017;69 Suppl 10:2500.

    OpenUrl
33. 33.↵
    1. Wallman JK,
    2. Jöud A,
    3. Olofsson T,
    4. Jacobsson LT,
    5. Bliddal H,
    6. Kristensen LE

    . Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. Rheumatology 2017;56:716–24.

    OpenUrl
34. 34.↵
    1. Rupp I,
    2. Boshuizen HC,
    3. Jacobi CE,
    4. Dinant HJ,
    5. van den Bos GA

    . Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Care Res 2004;51:578–85.

    OpenUrlCrossRef
35. 35.↵
    1. de Croon EM,
    2. Sluiter JK,
    3. Nijssen TF,
    4. Kammeijer M,
    5. Dijkmans BA,
    6. Lankhorst GJ,
    7. et al.

    Work ability of Dutch employees with rheumatoid arthritis. Scand J Rheumatol 2005;34:277–83.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Hazes JM,
    2. Taylor P,
    3. Strand V,
    4. Purcaru O,
    5. Coteur G,
    6. Mease P

    . Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology 2010;49:1900–10.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Almeida C,
    2. Choy EH,
    3. Hewlett S,
    4. Kirwan JR,
    5. Cramp F,
    6. Chalder T,
    7. et al.

    Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev 2016;6:CD008334.

    OpenUrlPubMed
38. 38.↵
    1. Dures E,
    2. Kitchen K,
    3. Almeida C,
    4. Ambler N,
    5. Cliss A,
    6. Hammond A,
    7. et al.

    “They didn’t tell us, they made us work it out ourselves”: patient perspectives of a cognitive-behavioral program for rheumatoid arthritis fatigue. Arthritis Care Res 2012;64:494–501.

    OpenUrlCrossRef
39. 39.↵
    1. Hewlett S,
    2. Ambler N,
    3. Almeida C,
    4. Blair PS,
    5. Choy E,
    6. Dures E,
    7. et al,
    8. RAFT Study Team

    . Protocol for a randomised controlled trial for Reducing Arthritis Fatigue by clinical Teams (RAFT) using cognitive-behavioural approaches. BMJ Open 2015;5:e009061.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Arthritis Research UK

    . Lessening the impact of fatigue: therapies for inflammatory rheumatic diseases (LIFT). [Internet. Accessed September 26, 2018.] Available from: www.arthritisresearchuk.org/research/grant-tracker-items/2016/lessening-the-impact-of-fatigue-therapies-for-inflammatory-rheumatic-diseases-lift.aspx
41. 41.↵
    1. Allaire SH,
    2. Li W,
    3. LaValley MP

    . Reduction of job loss in persons with rheumatic diseases receiving vocational rehabilitation: a randomized controlled trial. Arthritis Rheum 2003;48:3212–8.

    OpenUrlCrossRefPubMed